Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to⁶⁸Ga-DOTATATE/-TOC uptake

Abstract

SSTR-targeted radionuclide treatment has activity in a subset of patients with meningioma. Expression of SSTR via immunohistochemistry or radionuclide uptake might serve as a predictive biomarker for outcome to facilitate individualized treatment optimization in patients with uni- and multifocal meningiomas.